Belimumab (Benlysta) Now Approved in Saskatchewan, Nova Scotia, and New Brunswick for Lupus Nephritis

We are pleased to announce that Belimumab (Benlysta), a prescription drug used to treat adults with lupus-related kidney inflammation (active lupus nephritis), has been included in the Exception Drug Status (EDS) Benefit of the Saskatchewan and Nova Scotia Formularies as of May 1st, 2024 and New Brunswick as of June 24th, 2024. 

This is a significant advancement for lupus patients in Saskatchewan, Nova Scotia, and New Brunswick providing them with better access to essential treatments which will potentially enhance their quality of life and help them manage their symptoms more effectively.

Saskatchewan Formulary Inclusion: Belimumab has been included in the Saskatchewan Formulary Exception Drug Status (EDS) Benefit. For more information, please visit the following links:

Nova Scotia Formulary Inclusion: Belimumab has also been included in the Nova Scotia Formulary New Exception Drug Status Benefit. For more information, please visit the following links:

New Brunswich Drug Plans Formulary: Belimumab has also been included in the New Brunswick Drug Plans Formulary effective June 24, 2024. For more information, please visit the following links:

 

 

 

Lupus Blog Articles:

Scientists say they have identified a root cause of lupus — one that could pave the way for new treatments

Read

Belimumab (Benlysta) Now Approved in Saskatchewan, Nova Scotia, and New Brunswick for Lupus Nephritis

Read

Megakaryocyte: a new player in systemic lupus erythematosus

Read